Predicting serious drug side effects before they occur

	Tweet

All medications have side-effects from common aspirin to herbal remedies and from standard anticancer drugs to experimental immunosuppressants. However, predicting important side effects, serious adverse drug reactions, ADRs, is with current understanding almost impossible. However, a neural network technology trained with past data could give drug companies and healthcare workers a new tool to spot the potential for ADRs with any given medication.

Writing in the International Journal of Medical Engineering and Informatics, at team from the University of Medicine and Dentistry of New Jersey, has developed a new model that tests show is 99.87 percent accurate in predicting adverse drug reactions among 10,000 observations and 100 percent for non-serious ADRs.

Peng-fang Yen and colleagues Dinesh Mital and Shankar Srinivasan explain how obligatory warning labels on medication packaging often serve only to cause concern among patients, while products withdrawn from the market because of repeated ADRs repeatedly undermine the pharmaceutical industry. From the medical industry’s point of view and the perspective of patients, this is a growing concern that might be remedied with new technology, saving lives, reputations and healthcare costs.

The Food Drug Administration (FDA) in USA and the World Health Organization (WHO) monitor the safety of medications continuously. However, technology that could identify possible ADRs at the earliest possible stage of drug development, licensing and marketing is urgently needed, especially given the potential risks to patients in emerging areas of healthcare and the potential risks to shareholder confidence.

The team’s artificial neural network is a mathematical model of the biologic neural network embedded in computer software. It is trained by feeding in structural and physical data associated with known pharmaceutical products and any ADRs. A feedback loop discards those connections where a wrong prediction of a known outcome is made and as data are added the ANN builds up a network of correct “predictions”. After sufficient training, the ANN can then be tested on another set of pharmaceuticals and outcomes checked against known ADRs. If confidence is sufficiently high, the ANN can be used to predict ADRs for new drugs.

The team has demonstrated an accuracy of 95 percent in preliminary tests and is now using a much larger data set of 10,000 drug molecules and ADR observations to train the ANN to a much more refined level.

###

“Prediction of the serious adverse drug reactions using an artificial neural network model” in Int. J. Med. Eng. Informat., 2011, 3, 53-59

###

Contact: Peng-fang Yen

Inderscience Publishers

RELATED STORIES:
UK agency proposes ban on Alzheimer’s drugs   Misuse of ADHD drugs sends thousands each year to seek emergency hospital treatment   Warning over fake obesity drug for sale online   Cilexa safely curbs depression in the young   No increase in stroke risk with non-aspirin NSAIDs   Other Vioxx-like drugs also risky for heart   Lawyers to meet next week on Merck’s Vioxx - NYT   Rheumatoid Arthritis Drug Linked to Serious Infections and Cancers   Can Vigorous Exercise Curb Drug Abuse? Researchers Want to Find Out   FDA: Power to write drug labels could help public   Prescriptions for teens and young adults on the rise   Fertility drug may boost uterine cancer risk

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]